Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021

NEXT STORY
Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19
PREV STORY
Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine

author_avatar
NASDAQ Market News

BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market

MALVERN, Pa., Aug. 23, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless ...

author_avatar
NASDAQ Market News

OpGen Reports Second Quarter 2020 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News